Welcome to our dedicated page for TransDigm Group SEC filings (Ticker: TDG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TransDigm Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TransDigm Group's regulatory disclosures and financial reporting.
TransDigm Group’s Co-Chief Operating Officer Joel Reiss reported selling 414 shares of common stock on July 15, 2026 in multiple open-market or private transactions at prices between $1,229.6600 and $1,233.3800 per share, pursuant to a Rule 10b5-1 trading plan.
TransDigm Group Co-Chief Operating Officer Joel Reiss exercised stock options for 3,900 common shares at $284.97 per share and sold 3,486 shares of common stock on July 15, 2026, in multiple open market or private transactions carried out under a Rule 10b5-1 trading plan.
After these transactions, he directly holds 4,014 TransDigm common shares and 19,700 stock options with a $284.97 exercise price expiring on November 8, 2027.
TransDigm Group Incorporated elected to withdraw from its proposed acquisition of Stellant Systems, Inc. from Arlington Capital Partners. After reviewing the situation, the company concluded that continuing through the regulatory review process was no longer in the best interests of the company and its shareholders, citing uncertainty, the likely time required relative to contractual deadlines, and the opportunity cost versus other strategic acquisitions.
Following TransDigm’s withdrawal of its regulatory filing on July 10, 2026, the seller provided notice of termination of the transaction agreement. TransDigm states that it remains committed to a disciplined acquisition strategy and continues to evaluate opportunities it believes will enhance long-term shareholder value, while reiterating standard forward-looking statement risk disclosures.
TransDigm Group director W. Nicholas Howley reported an amended insider filing reflecting an “other” type transaction with no change in share ownership. The filing shows 0 common shares were transacted and 21,547.513 shares are held indirectly through the W. Nicholas Howley Family Trust u/a/d 4/23/99.
TransDigm Group director W. Nicholas Howley, through his family trust, reported an exercise-and-sell transaction in company stock. On June 18, 2026, the W. Nicholas Howley Family Trust exercised 10,132 stock options at an exercise price of $66.47 per share and acquired the same number of common shares.
The trust then sold 10,132 shares of TransDigm common stock in multiple open-market trades, at prices ranging from approximately $1,305 to $1,337.06 per share. Following these transactions, the trust’s indirect holdings in TransDigm common stock were 21,547.513 shares.
TransDigm Group INC director W. Nicholas Howley reported coordinated option exercises and share sales through his family trust. On June 18, 2026, the W. Nicholas Howley Family Trust u/a/d 4/23/99 exercised stock options for 10,132 shares of TransDigm common stock at an exercise price of $66.47 per share and sold 10,132 common shares in multiple open-market transactions.
The reported sale prices ranged around $1,305–$1,337 per share, with each line item giving a weighted average price for trades within a specific band. Following these transactions, the trust indirectly holds 21,547.513 shares of TransDigm common stock.
TransDigm Group director W. Nicholas Howley, through the W. Nicholas Howley Family Trust, reported an option exercise and related stock sales in TransDigm Group INC common stock. On June 18, the trust exercised options to acquire 10,132 shares at an exercise price of $66.47 per share.
That same day, the trust executed multiple open‑market sales totaling 10,132 shares of common stock at prices generally around $1,305 to $1,337 per share, as detailed in the reported weighted‑average price ranges. The transactions together represent an exercise‑and‑sell pattern carried out through the family trust’s indirect ownership.
TDG submitted a Form 144 notice relating to the proposed sale of Common Stock. The filing lists 30,396 shares under "Securities To Be Sold" with the transaction method noted as Stock Option Exercise and Cash, dated 06/18/2026.
The filing also records recent sales by Nicholas W. Howley of 10,168, 10,132, 10,132, and 10,132 shares on 02/18/2026, 03/18/2026, 04/20/2026, and 05/18/2026, respectively.
TransDigm Group reports that Co-Chief Operating Officer Joel Reiss exercised 3,900 stock options at $284.9700 per share into common stock on June 15, 2026, then sold 3,900 common shares in multiple trades at prices within $1,268.6100–$1,288.0400 per share. Following these transactions, he directly holds 3,600 common shares.
TDG reported Form 144 activity showing director/officer transactions. The filing lists three 10b5-1 sales of 3,900 shares each on 03/16/2026, 04/15/2026 and 05/15/2026 with proceeds of $4,850,431.17, $4,993,786.98 and $4,500,966.21 respectively. The filing also lists 11,700 shares to be sold on 06/15/2026 via an exercise of stock options for cash, brokered through Morgan Stanley Smith Barney LLC.